- Home
- ATPC vs VIVS Comparison
ATPC vs VIVS Comparison
Compare ATPC & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATPC | VIVS |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | Malaysia | United States |
| Employees | N/A | 9 |
| Industry | Medical/Nursing Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2M | 2.5M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | ATPC | VIVS |
|---|---|---|
| Price | $2.45 | $0.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.6M | ★ 4.8M |
| Earning Date | 04-13-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,524,262.00 | N/A |
| Revenue This Year | N/A | $42.38 |
| Revenue Next Year | N/A | $15.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.23 | N/A |
| 52 Week Low | $0.05 | $0.41 |
| 52 Week High | $8.50 | $5.30 |
Technical Indicators
Market Signals| Indicator | ATPC | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 43.73 | 18.20 |
| Support Level | $1.93 | N/A |
| Resistance Level | $2.55 | $1.62 |
| Average True Range (ATR) | 0.34 | 0.12 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 0.00 | 0.42 |
Price Performance
Historical ComparisonAbout ATPC Agape ATP Corporation
Agape ATP Corp through its subsidiaries is engaged in providing health and wellness products and health solution advisory services. The principal activities of the company is to supply high-quality health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation, anti-aging and products designed to improve the overall health system of the human body and various wellness programs. Its segments include: Skin care, health and wellness segment includes the provision of health and wellness products and health solution advisory services; and Green energy segment includes providing renewable energy products, technical solutions, installations and maintenance services. It derives maximum revenue from Skin care, health and wellness segment.
About VIVS VivoSim Labs Inc.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.